Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial
Published Online: 2019-01-?
Journal: The Lancet Oncology•Publisher: Elsevier BV
Authors: Alessandra Tedeschi•Bertrand Anz•Carol Moreno•Cathy Zhou•Chih-Jian Lih•Danelle F James•Devinder Gill•Dina Ben-Yehuda•Emily Hsu•Fatih Demirkan•Fong Clow•Ian W Flinn•Jan Novak•John G Gribben•Loree Larratt•Lori Styles•Martin Simkovic•Olga Samoilova•Richard Greil•Vladimir Strugov
